Open in app

SII is seeking government approval to manufacture and stockpile the qHPV vaccine to prevent cervical cancer.

Total Views:
Total Likes:
Published By:
Peeyush Ghalot
Published On:
(Image Courtesy: - Medical Buyer)

After completing phase 2/3 clinical trials, the Serum Institute of India has applied to the government for permission to manufacture and stockpile the indigenously developed Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer in order to ensure its early availability in the country. The company will soon apply to the Drugs Controller General of India (DCGI) for market authorization and a production licence for the vaccine. The production of qHPV takes five to six months, according to Prakash Kumar Singh, director of Government and Regulatory Affairs at SII, in a letter to the Union health ministry. According to the application, lakhs of women are diagnosed with cervical cancer each year, with a high fatality rate. Cervical cancer is the second most common malignancy among women in India between the age of 15 and 44. Our country is currently solely reliant on foreign manufacturers for cervical cancer vaccine, and our citizens are obligated to purchase these vaccines at exorbitant prices. SII has been working for more than five years under the guidance of our CEO Adar C Poonawalla to make an indigenous world-class vaccine against cervical cancer, known as the Quadrivalent Human Papillomavirus vaccine, available," Singh is claimed to have written in his letter. According to an official source familiar with the situation, if the government approves the SII's proposal, it will save time in incorporating the indigenously developed qHPV into the Universal Immunization Program.

Reference: -